Abstract:Objective This research is to increase our ability to make more accurate diagnosis about phaechromocytoma and paraganglioma (PPGLs) patients with normal plasma free MNs. Methods A retrospective research was conducted in our hospital’ selectronic data base recorded from 2004 to 2012, where pathological confirmed phaechromocytoma(Pheos) and paragangliomas (PGLs) patients were included for analyzing the clinical symptoms and signs, endocrine hormone level, enhanced-contrast CT and radionuclide imaging feathers. Patients were assigned to Group 1 with normal plasma free MNs and Group 2 with elevated plasma free MNs. The above characteristics were compared between both groups. Results 189 patients were included for comprehensive analysis, of which 24 patients were enrolled into Group 1. The prevalence of hypertension, paroxysmal hypertension, no less than two symptoms of paroxysmal episodes of headache, sweating and palpitations, weight losses in Group 1 were significantly lower than patients in Group 2 (P<0.05). The average 24-h urinary epinephrine, dopamine and norepinephrine in Group 1 were lower than the matched group, especially for the average 24-h urinary norepinephrine, which was 1/6 that of patients in Group 2 (P=0.001). Despite the prevalence of hyperattenuation and heterogenous enhancement decreased by 14.8% compared to that of patients in Group 2 (P=0.101), it was still predominant among all enhancement patterns of enhanced-contrast CT in Group 1. There was no significant difference when it came to the prevalence of all kinds of enhance patterns on enhanced-contrast CT between both groups (P>0.05). Radionuclide imaging showed a similar positive detecting rate between two groups (P=1.000). Conclusion The suspicious clinical symptoms and signs for PPGLs were not that apparent in PPGLs patients with normal plasma free MNs, who were associated with a decreased catecholamine secretion. Hyperattenuation and heterogenous enhancement at enhanced-contrast CT or positive radionuclide imaging may attribute to a more accurate diagnosis of those patients than biochemical tests.

Diagnosis of malignant chromaffin-cell tumor

[Malignant Pheochromocytoma: Diagnosis and Treatment].

Malignancy in pheochromocytomas

Predictive Factors for Malignant Pheochromocytoma: Analysis of 136 Patients.

Recent progress of diagnosis of malignant phaeochromocytoma

Development Of Differential Diagnosis For Benign And Malignant Pheochromocytomas

The Diagnosis and Treatment of Malignant Paraganglioma

Multi-disciplinary diagnosis and treatment of a malignant pheochromocytoma with multiple metastases

[Analysis of Clinical Characteristics of Paraganglioma in 42 Patients].

Research Progerss on Molecular Biochemistry of the Differenciation of Benign and Malignant Pheochromocytoma

Diagnostic features and therapeutic strategies for malignant paraganglioma in a patient: A case report

Clinical Syndromes And Genetic Screening Strategies Of Pheochromocytoma And Paraganglioma

CT Diagnosis of Malignant Pheochromocytoma:a Report of Five Cases

Recent progress in molecular classification of phaeochromocytoma and paraganglioma

A novel diagnostic method of Raman spectroscopy for malignant pheochromocytoma/paraganglioma

Imaging of Pheochromocytomas and Paragangliomas

Overexpression Of Erbb-2 Was More Frequently Detected In Malignant Than Benign Pheochromocytomas By Multiplex Ligation-Dependent Probe Amplification And Immunohistochemistry

The clinical feathers of phaechromocytoma and paraganglioma with normal plasmal free MNs

The Expression of Snail, Galectin-3, and IGF1R in the Differential Diagnosis of Benign and Malignant Pheochromocytoma and Paraganglioma

Genetics and imaging of pheochromocytomas and paragangliomas: current update

Diagnosis and Outcome of Cardiac Paragangliomas: A Retrospective Observational Cohort Study in China